Invivyd ( (IVVD) ) has released its Q1 earnings. Here is a breakdown of the information Invivyd presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Invivyd, Inc. is a biopharmaceutical company focused on developing innovative antibody treatments for viral infectious diseases, particularly SARS-CoV-2, utilizing a proprietary technology platform.
In the first quarter of 2025, Invivyd reported net product revenue of $11.3 million for its monoclonal antibody PEMGARDA, despite a strategic transition to an internalized sales force. The company aims to achieve near-term profitability by the first half of 2025, supported by a strong cash position and a $30 million non-dilutive term loan facility.
Key financial metrics for Q1 2025 include a decrease in research and development expenses to $10.6 million from $31.2 million in the previous year, and an increase in selling, general, and administrative expenses to $16.8 million. The net loss for the quarter was reduced to $16.3 million from $43.5 million in Q1 2024. Invivyd’s cash and cash equivalents stood at $48.1 million as of March 31, 2025.
The company continues to expand its pipeline, with ongoing trials for VYD2311, a novel monoclonal antibody candidate. Despite a recent FDA declination to expand PEMGARDA’s emergency use authorization, Invivyd remains focused on addressing unmet medical needs and exploring new targets beyond SARS-CoV-2.
Looking ahead, Invivyd is optimistic about its growth prospects, driven by the re-acceleration of PEMGARDA revenue and strategic financial management. The company is committed to advancing its pipeline and achieving profitability in the near term.